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a  b s t  r a c  t
Objective:  To  assess  the levels  of a tobacco-specific  nitrosamine  (NNAL)  in non-smokers  passively  exposed
to  the  second-hand aerosol (SHA)  emitted  from users of electronic  cigarettes  (e-cigarettes).
Method:  We  conducted  an  observational study  involving  55 non-smoking  volunteers divided  into  three
groups:  25  living  at home with  conventional  smokers, 6 living  with  e-cigarette  users,  and  24 in control
homes  (smoke-free  homes).  We  obtained  urine  samples  from all volunteers  to determine  NNAL.
Results:  We  detected  NNAL  in the  urine  of volunteers  exposed  to  e-cigarettes  (median:0.55  pg/mL;
interquartile range:  0.26-2.94 pg/mL). The percentage  of urine  samples  with  quantifiable  NNAL  differed
significantly  among  the  three groups  of  homes:  29.2%, 66.7% and  76.0%,  respectively  (p  = 0.004).
Conclusions: We  found  NNAL  nitrosamine  in urine  samples from people  exposed  to  SHA  from  e-cigarettes.
However,  these  results could  be  confirmed with  more  studies  with  larger  sample  sizes.
© 2018  SESPAS. Published  by  Elsevier España,  S.L.U. This  is an open access article under  the  CC
BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Exposición  pasiva  al aerosol  del  cigarrillo  electrónico:  estudio  piloto




Aerosol de segunda mano
Cigarrillo electrónico
r  e  s  u m  e  n
Objetivo: Evaluar los niveles de  nitrosamina  específica del tabaco (NNAL)  en  no fumadores  expuestos
pasivamente  al aerosol emitido por usuarios  de  cigarrillo electrónico.
Método:  Estudio  observacional  de  una muestra de  55 voluntarios  no fumadores  divididos  en  tres  grupos:
25  que vivían en  una  casa con  un fumador de  tabaco convencional,  6  que  vivían  en  una  casa con un
usuario  de  cigarrillo  electrónico  y  24 que  vivían en  casas  controles  (hogares  libres  de  humo).  Se  obtuvo
una  muestra  de  orina de  todos  los  voluntarios  para determinar las  concentraciones  de  NNAL.
Resultados:  Se  detectaron valores de  NNAL  en  los voluntarios  expuestos  al cigarrillo  electrónico  (mediana:
0,55  pg/ml;  rango  intercuartílico:  0,26-2,94 pg/ml).  El porcentaje  de  voluntarios  con concentraciones
cuantificables  de NNAL  fue estadísticamente  diferente entre  los  tres  grupos  de casas:  29,2%,  66,7%  y  76%,
respectivamente  (p =  0,004).
Conclusiones: Se  encontraron  valores  de  NNAL  en  los no fumadores  expuestos pasivamente  al aerosol del
cigarrillo  electrónico. Estos  resultados  tienen  que  confirmarse  con muestras  más  grandes.
©  2018  SESPAS. Publicado  por  Elsevier  España,  S.L.U. Este  es un  artı́culo Open  Access bajo  la licencia
CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
∗ Corresponding author.
E-mail address: jmmartinez@uic.es (J.M. Martínez-Sánchez).
Introduction
As electronic cigarettes (e-cigarette) use has been grown, more
concerns have appeared about the exposure of bystanders to sec-
ondhand aerosol (SHA) from these devices. This exposure results
https://doi.org/10.1016/j.gaceta.2018.07.016
0213-9111/© 2018 SESPAS. Published by Elsevier España, S.L.U. This is  an open access article under the CC  BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Table 1
Characteristics of the e-liquids and e-cigarettes in this study.






Totally Wicked Menthol 11 62.7 mg Cigalike KangerTech KR808D-1
Totally  Wicked Marlboro 24 48  mg  e-Go E-go C Totally Wicked
Puff  Menthol 18 180 mg e-Go Puff
Puff  Keen Tobacco 9 27  mg  e-Go e-Go-T Upgrade Joyetech
Free  Life Mint 6 19.2 mg e-Go e-Go-T Joyetech
Unknown Mint 6 12.85 mg  e-Go Unknown
a As stated by the e-liquid manufacturer.
b As  reported by the e-cigarettes users.
when the aerosol inhaled by  users (firsthand aerosol) is exhaled
into the air where it may  be breathed by  non-users.1 This exposure
is worrying because several studies have found toxic and carcino-
genic substances in  the aerosol (both firsthand and secondhand)
generated by e-cigarettes.1,2
Tobacco-specific nitrosamines have been found in the aerosol
generated by e-cigarettes3,4 and also in  some brands of e-cigarette
liquids,5,6 although not all of the studies have detected tobacco-
specific nitrosamines in  the samples studied,7 a finding that
indicates that important differences between brands may  exist.
Despite the potential presence of toxic substances in  these aerosols,
exposure to SHA from e-cigarettes has received scant attention
according to a recent systematic review.2
For these reasons, we  conducted the present study to  assess
the levels of NNAL, nitrosamine associate with lung cancer,8 in
urine samples in a group of non-smokers exposed to SHA from e-
cigarette users in their homes under real-life conditions. Moreover,
we compared these concentrations with those of non-smokers pas-
sive exposed to conventional cigarettes in  their homes and with
those of non-smokers not exposed to aerosol from e-cigarettes
neither conventional cigarettes in  their homes.
Method
We  conducted a study of passive exposure to electronic and
conventional cigarettes in real-use conditions. A tobacco-specific
nitrosamine (NNAL) was determined in urine samples from a
group of volunteers. We recruited a  convenience sample of 55
non-smoking volunteers from different homes, distributed as fol-
lows: 25 living at home with conventional smokers, 6 living with
e-cigarette users, and 24 from control homes (without the pres-
ence of either conventional smokers or e-cigarette users). We also
enrolled the 6 e-cigarette users who lived with the non-smoking
volunteers. Participants living with e-cigarette users or smokers,
and the e-cigarette users, provided self-reported data affirming
that their only source of exposure to SHA from e-cigarette or
tobacco smoke during the one-week study period was  in  their home
and also confirmed that they did not use any tobacco products.
These were the conditions for study inclusion that volunteers (non-
smokers and e-cigarette users) agreed to at study enrolment. The
self-reported lack of exposure in  settings other than their homes
(work, leisure time, and transport) was confirmed by a  personal
interview. In addition, all volunteers, including the 6 e-cigarettes
users, declared that they did not use other tobacco products or  nico-
tine replacement therapy during the study period. This pilot study
is part of a large project which the main objective is to assess the
impact of Spanish legislations and the passive exposure to second-
hand smoke of conventional cigarettes at home. We conducted this
pilot study due to the increasing popularity of the e-cigarettes and
the lack of evidence worldwide about passive exposure to SHA from
e-cigarettes. The fieldwork was conducted in  Barcelona, Spain, in
2012.
The characteristics of the e-liquids and e-cigarettes used in this
study are described in Table 1.
We  obtained urine samples for NNAL analysis by liquid
chromatography coupled with tandem mass spectrometry with
multiple reaction monitoring (LC/MS/MS). We measured the NNAL
concentration in picograms per milligram of creatinine (pg/mg)
because the NNAL concentrations were adjusted for creatinine. The
limit of quantification (LOQ) of NNAL was 0.25 pg/mg in  5 mL  of
urine for a 1 mg/mL  of creatinine excretion.
Data analysis
We calculated the percentage of the volunteers with NNAL
concentrations over the LOQ. For  the samples with NNAL concen-
trations below the LOQ, we assumed the half of the LOQ value
to compute the medians and interquartile ranges (IQRs). Given
the skewed distribution of NNAL we compared the concentration
among three types of homes with the Kruskal Wallis test. Then, we
compared the concentration of NNAL among groups by means of
the Chi square test and the Wilcoxon test for independent samples.
We  also calculated the Spearman correlation among NNAL concen-
trations of the non-smokers exposed to  e-cigarettes and users of
e-cigarettes who lived with them.
Results
Statistically significant differences were found among the three
groups of homes in  the percentage of volunteers with quantifi-
able levels of NNAL in  urine: 29.2%, 66.7%, and 76% (Table 2).
After adjusting for multiple comparisons, differences in NNAL urine
concentration were on the borderline of statistical significance
between non-smokers in control homes and those exposed to
tobacco smoke at home (Table 2).
As  shown in  Table 3,  we  quantified traces of NNAL in the urine
samples of four out of the six volunteers exposed to SHA from
e-cigarette users. Spearman’s correlation of the NNAL levels in  urine
of the e-cigarettes users and the volunteers exposed to SHA from
e-cigarette users was 0.943 (p  =  0.005).
From six  e-cigarette users, NNAL was quantifiable in the urine
sample (median: 2.86 pg/mg; IQR: 0.36-6.92 pg/mL) (data not
shown).
Discussion
Our results show that there are quantifiable levels of NNAL in
urine among bystanders exposed to SHA from e-cigarette users
at home. Moreover, we also found a strong correlation between
NNAL levels in urine among e-cigarette users and those of  the non-
smokers exposed to SHA at home from e-cigarette users. A previous
study conducted in  698 individuals (532 of them non-smokers)
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Table  2
Percentages of samples with detectable levels of NNAL and median (pg/mL) and interquartile range of NNAL in urine samples of the non-smokers volunteers according to
passive exposure at home (non-exposed or control homes, exposed to secondhand aerosol from e-cigarettes users, and exposed to tobacco smoke).
NNAL in urine samplesa
n  Percentage of samples with
detectable NNAL
Median (IQR)
Non exposed (control homes) 24 29.2% 0.33 (0.16 - 0.51)
Exposed to e-cigarettes’ aerosol 6 66.7% 0.55 (0.26 - 2.94)







a Adjusted for urinary creatinine.
b Pearson’s Chi square.
c Comparison among volunteers from the three types of homes (non-exposed or smoke-free homes, exposed to  e-cigarettes’ aerosol, and conventional cigarettes) by
Kruskal  Wallis test.
d Comparison between volunteers from smoke-free homes (control homes) and e-cigarettes homes by Wilcoxon test for independent samples.
e Comparison between volunteers from smoke-free homes (control homes) and conventional cigarettes homes by Wilcoxon test for independent samples.
f Comparison between volunteers from e-cigarettes homes and conventional cigarettes homes by  Wilcoxon test for independent samples.
Table 3
Levels of NNAL in  the samples of urine of the e-cigarettes user and non-users exposed




Exposed to  secondhand aerosol
from e-cigarette users
Urine samples (pg/mL)a
Home 1 0.37 <  0.56
Home 2 0.33 <  0.44
Home 3 6.1 3.0
Home 4 0.42 0.44
Home 5 5.3 0.67
Home 6 9.4 2.9
a Adjusted for urinary creatinine.
The limits of quantification were 0.25 pg/mL for NNAL in 5 mL of urine for a 1 mg/mL
of  creatinine excretion.
also found levels of NNAL in saliva among non-smokers exposed
to  secondhand smoke.9
Vogel et al.10 found that the levels of NNAL in  urine (with-
out adjusting for creatinine) ranged from 6.27 to 12.54 pg/mL,
among non-smokers exposed to secondhand smoke from conven-
tional cigarettes. In  our study, the levels were lower in participants
who were passively exposed to  e-cigarettes (median: 0.47  pg/mL;
range: 0.125-3.2 pg/mL) and to conventional cigarettes (median:
0.52 pg/mL; range: 0.125-8.3 pg/mL). These differences could be
explained partially by the differences on the sample size  of both
studies and the inclusion criteria of our study (at home was  the only
source of exposure of our non-smokers volunteers and e-cigarette
users in the last week). Moreover, other potential explanation
could be the difference in  the duration and intensity of expo-
sure among studies, and the measurement bias inter-laboratory.
Although the levels of NNAL among non-smokers exposed passively
to e-cigarettes are very low8 there is no safety level of exposure and
the risk increases with the intensity and duration of exposure.11,12
The average NNAL concentration in  urine (unadjusted for cre-
atinine) of smokers is  around 300 pg/mL.13 We also found levels
of NNAL in users of electronic cigarettes (median without adjust-
ing for creatinine: 2.6 pg/mL; range: 0.33-9.7 pg/mL). Compared
to smokers, these results are orders of magnitude lower10,13 but
this magnitude was similar to  those found in  e-cigarette users in  a
previous study.14
Our results should be  interpreted with caution due to the small
number of volunteers exposed to e-cigarette users at home and
the  differences brands of e-cigarettes. In addition, although one
inclusion criterion was  that participants’ only permitted exposure
to  smoking during the study period was at home, we cannot be
sure that participants’ did  not receive any additional unreported
exposure. In an effort to avoid this limitation all participants did
not use nicotine replacement therapy and they were instructed to
avoid exposure to e-cigarettes and conventional cigarettes except
at home.
In  conclusion, we  found quantifiable levels of NNAL in  urine
samples of non-smokers passively exposed to SHA from e-
cigarette users. However, these results could be confirmed with
more studies.
What is known about the topic?
Interest, popularity and awareness of  electronic cigarettes
(e-cigarettes) have substantially increased in recent years. As
e-cigarette use has been grown, more concerns have appeared
about the exposure of bystanders to secondhand aerosol from
these devices. This exposure results when the aerosol inhaled
by users (firsthand aerosol) is  exhaled into the air where it  may
be breathed by non-users.
What does this study add to the literature?
Our results show that there are quantifiable levels of NNAL
in urine among bystanders exposed to  secondhand aerosol
from e-cigarette users in the home. We  also found a very strong
correlation between carcinogenic NNAL levels in urine among
e-cigarette users and  those of the non-smokers exposed to
secondhand aerosol at home from e-cigarette users.
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